Log in
Enquire now
‌

US Patent 9868722 Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex

Patent 9868722 was granted and assigned to Cleave Biosciences, Inc. on January, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Cleave Biosciences, Inc.
Cleave Biosciences, Inc.
0
Current Assignee
Cleave Biosciences, Inc.
Cleave Biosciences, Inc.
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
98687220
Patent Inventor Names
Han-Jie Zhou0
David Wustrow0
Date of Patent
January 16, 2018
0
Patent Application Number
151038280
Date Filed
December 10, 2014
0
Patent Primary Examiner
‌
Deepak Rao
0
Patent abstract

Monocyclic pyrimidine and pyridine compounds having a benzyl amine substituent at the 4 position and a 5:6 bicyclic heteroaryl substituent at the 2 position of the pyrimidine or pyridine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9868722 Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.